AIMMS Seminar: H. Charles Manning, PhD


10.00 - 11.00h

Auditorium, O|2 Lab Building

AIMMS Seminar: Precision Imaging Metrics for Quantitative Cancer Medicine

H. Charles Manning, PhD (Vanderbilt University Center for Molecular Probes, Vanderbilt University, Nashville, USA)

Amsterdam Institute for Molecules, Medicines and Systems


Conference / Symposium

H. Charles Manning, PhD (Vanderbilt University Center for Molecular Probes, Vanderbilt University, Nashville, USA) will provide an AIMMS Seminar on 12 December entitled 'Precision Imaging Metrics for Quantitative Cancer Medicine'.

You are all cordially invited!


Cancer diagnosis algorithms routinely use medical imaging of one or more types, but the clinical imaging modalities that are most-heavily relied upon provide primarily anatomical and structural information. These modalities, namely X-Ray Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), can provide quantitative data. However, a consequence of relying extensively upon these modalities, particularly to predict response to therapy, is that many of the cellular and molecular features of tumors quantifiable by imaging remain unannotated.

Positron Emission Tomography (PET) is a clinical molecular imaging modality with the potential to advance precision medicine in oncology. Employing specialized radiopharmaceuticals referred to as ‘probes’ or ‘tracers’ and administered to subjects for imaging, non-invasive PET allows quantification of the cellular and molecular underpinnings of diseases on a patient-by-patient basis. PET provides ways to detect disease at early, potentially curable stages, identify patients likely to respond to certain treatments, and predict early response to therapy.

Despite this, a lack of specific and biologically validated tracers limits the breadth of biological and clinical questions addressable with PET. While applicable in many clinical settings, by far, oncology suffers the greatest gap spanning clinically unmet needs and routinely available PET tracers. The most widely used PET tracer in humans, and the only tracer widely distributed and routinely reimbursed in the US, is 2-deoxy-2-(18F)fluoro-D-glucose (FDG). The current lack of clinically utilized PET tracers is a shame because one molecular imaging readout (e.g., glucose metabolism) is truly insufficient to adequately profile the distinguishing features of a patient’s tumor.

Our vision is that future clinical imaging workflows will include PET imaging with many tracers, typically within the same visit to the PET center. Relevant tracers may include so-called ‘theranostics’, as well as ligands or substrates that provide biologically orthogonal readouts of signal transduction or metabolism. Such an ambitious approach will necessarily require a major paradigm shift in tracer production, distribution and delivery. Efforts within Vanderbilt’s Center for Molecular Probes to address this critical gap will be discussed, as well as future possibilities to combine multi-modality molecular imaging into large integrated data sets that complement contemporary, high information content personalized approaches.